Results 11 to 20 of about 46,038 (143)

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.

مجلة كلية الطب, 2015
Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy .Treatment with infliximab gives great improvement to a large numbers of patients with RA ,however, in some patients after prolonged treatment infliximab can ...
Mohammed A. Al-Karkhi, Muhammed M. Al-Ani, Nizar A. Jassim   +2 more
doaj   +1 more source

Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis

GMS Ophthalmology Cases, 2023
Objective: To present a case with infliximab-induced retrobulbar optic neuritis.Case description: A 58-year-old woman presented to our clinic with a two-day history of blurred vision in her right eye.
Dündar, Sema, Yaşar, Mimbay, Çakmak, Harun, Kıylıoğlu, Nefati, Ünsal, Alparslan   +4 more
doaj   +1 more source

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

BMC Musculoskeletal Disorders, 2012
Background To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients with low disease activity and if serum trough levels are stable and reliable longitudinally we conducted a prospective cohort study Methods In a ...
van der Maas Aatke, van den Bemt Bart JF, Wolbink Gertjan, van den Hoogen Frank HJ, van Riel Piet LCM, den Broeder Alfons A   +5 more
doaj   +1 more source

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.

PLoS ONE, 2015
ObjectiveIn patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg).
Dario Sorrentino, Marco Marino, Themistocles Dassopoulos, Dimitra Zarifi, Tiziana Del Bianco   +4 more
doaj   +1 more source

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease

BMJ Open Gastroenterology, 2021
Background Infliximab is an efficacious therapy for inflammatory bowel disease and may play a role in management of some extraintestinal manifestations.
Daniel J Stein, Andres J Yarur, Shaina Sekhri, Bharat Rao, Akanksha Mohananey, Poonam Beniwal-Patel, Alexandra Bruss   +6 more
doaj   +1 more source

Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy.

PLoS Biology, 2019
During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy.
Yun-Chi Lu, Chih-Hung Chuang, Kuo-Hsiang Chuang, I-Ju Chen, Bo-Cheng Huang, Wen-Han Lee, Hsin-Ell Wang, Jia-Je Li, Yi-An Cheng, Kai-Wen Cheng, Jaw-Yuan Wang, Yuan-Chin Hsieh, Wen-Wei Lin, Tian-Lu Cheng   +13 more
doaj   +1 more source

Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis

Case Reports in Dermatology, 2017
A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled ...
Yuki Matsuura-Otsuki, Takaaki Hanafusa, Hiroo Yokozeki, Kyoko Watanabe   +3 more
doaj   +1 more source

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis

Respiratory Research, 2022
Background Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis.
Abdullah Sakkat, Gerard Cox, Nader Khalidi, Maggie Larche, Karen Beattie, Elisabetta A. Renzoni, Nilesh Morar, Vasilis Kouranos, Martin Kolb, Nathan Hambly   +9 more
doaj   +1 more source

Specialized enteral nutrition therapy in Crohn’s disease patients on maintenance infliximab therapy: a meta-analysis

Therapeutic Advances in Gastroenterology, 2015
Objectives: Many patients with Crohn’s disease on infliximab maintenance therapy have recurrent symptoms despite an initial clinical response. Therefore, concomitant therapies have been studied.
Douglas L. Nguyen, Lena B. Palmer, Emily T. Nguyen, Stephen A. McClave, Robert G. Martindale, Matthew L. Bechtold   +5 more
doaj   +1 more source

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients

Inflammatory Intestinal Diseases, 2021
Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD).
Manuel Sutter, Petr Hruz, Jan Hendrik Niess   +2 more
doaj   +1 more source